TENX Stock Summary and Trading Ideas (Tenax Therapeutics | NASDAQ:TENX)

Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.

Tenax Therapeutics trades on the NASDAQ stock market under the symbol TENX.

As of March 13, 2026, TENX stock price declined to $13.84 with 263,648 million shares trading.

TENX has a beta of 0.46, meaning it tends to be less sensitive to market movements. TENX has a correlation of 0.02 to the broad based SPY ETF.

TENX has a market cap of $86.41 million. This is considered a Micro Cap stock.

In the last 3 years, TENX traded as high as $61.20 and as low as $2.77.

The top ETF exchange traded funds that TENX belongs to (by Net Assets): VTI, VXF, DFAS, DFAC, DCOR.

TENX has outperformed the market in the last year with a price return of +117.6% while the SPY ETF gained +21.4%. TENX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +33.5% and +15.3%, respectively, while the SPY returned -2.6% and -3.5%, respectively.

TENX support price is $13.44 and resistance is $14.94 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TENX shares will trade within this expected range on the day.